Among SLE pts, males have a higher risk of infection compared to females. Males have a (6X) higher prevalence of pneumonia and women have more urinary tract infections. Retrospective study of 119 SLE pts (107 females, 12 males) https://t.co/M12G7hT340 https://t.co/SG7eSGzpXh

QD Clinic - CREST or More? Is this CREST or Diffuse PSS? Features Dr. Jack Cush. QD Clinics - lessons from the clinic, sponsored by RNL2025 in Dallas, TX; Feb 8 & 9, 2025 Register at https://t.co/2dcFVgu8z6 https://t.co/eA1GijHiYu https://t.co/3EmN9WAyIR

Dazukibart Effective in Adults with Dermatomyositis Lancet reports that the use of dazukibart, a selective monoclonal antibody against interferon B (IFNβ), was clinically effective in reducing disease activity in adults with active dermatomyositis (DM).… https://t.co/WwvAhPuoGV https://t.co/M0yECxsvcr

Eltrombopag, a Potential New Treatment for ITP A pilot trial has shown a thrombopoietin receptor agonist, eltrombopag (Promacta), to be effective in connective tissue disease-related (CTD), refractory immune thrombocytopenia (ITP). https://t.co/hYSAEKOjq5 https://t.co/QzBNA3SWVo

Pan American Health Org announces that in 2024 saw largest dengue epidemic in the Americas, >12.6 million cases reported (3x record in 2023); 21,000 severe w/ 7,700 deaths; 90% from Argentina, Brazil, Colombia, Mexico. Most USA cases (FL, HI, TX, AZ, CA) seen in travelers… https://t.co/nhuJIP9Y8v https://t.co/QLju8uRKZ8

Alive in 2025 (1.10.2025) Dr. Jack Cush brings in the new year with a review of the latest from RheumNow. https://t.co/Cw94fF5nFi https://t.co/6c3Gl6GOCY

SetPoint Medical has applied to FDA for pre-market approval of Vagal nerve neuroimmune modulation device to Rx mod-severe #RA, not responding to 2 biologics. Based on RESET-RA 242 pt, 12 wk RCT showing ACR20=35% vs 24% PBO resp. SAE only 1.7%. https://t.co/d8RfXBFUSS https://t.co/Fq1qkfo1NM

Just published, a new review of Axial spondyloarthritis from Baraliakos, et al in Lancet! https://t.co/AuMTLo8iQO https://t.co/1icGoXKfB9

Have a rheumatology question or case for Dr. Cush? Record it here and we'll feature it on an upcoming podcast. Tell us your name and where you practice rheumatology. https://t.co/UMrunimVv6 https://t.co/yZNdnAWCy2

RheumThoughts: Overlap Syndrome with ILD How would you manage a patient with Overlap (anti-synthetase) syndrome, ILD, polyarthritis and myositis? https://t.co/4RyV1zkphe https://t.co/qTZ4JYlJmW

VA (Veterans) study of 531 RA-ILD (among 9,701 incident RA) vs 68,852 matched controls - finds exposure to fire smoke PM2.5 assoc w/ RA-ILD/aOR 1.98 (but not RA). NOx, ozone, and PM10 assoc w/ seroneg. RA risk (aOR 1.16-1.25) . Pollution increases risk of RA & RA-ILD… https://t.co/AuG4rRtx4r https://t.co/XyHtjrSfhi

Network metanalysis of 9 RCTs, 3699 patients looked at small molecule Rx in #PsA. With ACR 50/70, PASI 75, & HAQ-DI @ wk 12-16, UPA was > ADA in PASI75 (RR 1.2); Deucravacitinib > Otezla at HAQ (RR −0.16) no OTHER SIGNIF differences observed https://t.co/T0eMkXrxQX https://t.co/FCkbuhi1ze